MediPharm Labs Corp. announced through its wholly owned subsidiary, it has signed a new agreement with MT Pharma, based in Malta to supply premium, GMP certified, finished dose cannabis oil for patients. MediPharm Labs continues to see significant growth opportunities ahead as numerous pharmaceutical, medical, wellness customers and brands continue to chose MediPharm as their preferred partner for turnkey GMP certified manufacturing and proven global supply chain distribution capabilities. Under MedPharm Labs Australia Pty. Ltd.’s two year-agreement, subject to further renewals, with MT Pharma, MediPharm Labs will provide pre-formulated GMP certified full spectrum cannabis concentrates that will be distributed to patients through pharmacies that will complete final formulation and fill. MediPharm Labs is encouraged by the pace of growth in emerging international cannabis markets with large populations and strictly defined GMP regulatory frameworks for cannabis, particularly Europe, Latin America and the United States. In the last three months, MediPharm has completed export of cannabis based derivative products to multiple customers in Germany, Peru and Australia, and has expanded its product offerings and distribution footprint in Canada. The Company expects to begin exports to other countries this year including Brazil, Malta, Denmark and New Zealand, where there are strict restrictions and in almost all cases only companies with pharmaceutical GMP certification are permitted to import product.